DIABETES MEDICATION SIDE EFFECTS
Charleston, IL Attorneys For Saxagliptin & Alogliptin Lawsuits
On April 5, 2016, the Federal Drug Administration (FDA) issued new warnings concerning diabetes medications containing Saxagliptin and Alogliptin. The drugs at issue include Onglyza, Kombiglyze XR, Nesina, Kazano, and Oseni. These drugs are recommended for use, with diet and exercise, to lower blood sugar in adults with type 2 diabetes. If you took or are taking one of these medications and experienced adverse effects or injuries, you may have grounds for a lawsuit against the pharmaceutical company or other potentially at-fault party. Spiros Law, P.C. can advise you of your options and your legal rights, based on over 100 years of collective knowledge and experience. Since opening our doors more than 25 years ago, our Charleston, IL drug injury attorneys have served Central and Southern Illinois.
Call (217) 516-3451 or fill out our online contact form for a free, confidential review of your case.
FDA Issues Warnings Regarding Popular Diabetes Medications
According to the FDA, in two large clinical trials, the FDA recommended that “health care professionals should consider discontinuing medications containing Saxagliptin and Alogliptin in patients who develop heart failure and monitor their diabetes control. If a patient’s blood sugar level is not well controlled with their current treatment, other diabetes medicines may be required.” The FDA further recommended that patients taking these medications should “contact their health care professionals right away if they develop signs and symptoms of heart failure such as unusual shortness of breath during daily activities, trouble breathing when lying down, tiredness, weakness, or fatigue, or weight gain with swelling in the ankles, feet, legs or stomach.” However, the FDA further notes that “patients should not stop taking their medicine without first talking to their health care professionals.” Beyond the warnings by the FDA, in a 2013 article appearing in The New England Journal of Medicine, the authors studied 16,492 diabetic patients, 8,200 of which were taking Saxagliptin. The authors found that the patients taking Saxagliptin were at an increased risk of heart failure.
